BHARAT BIOTECH

History

Year	Detail
1996	Dr. Krishna M. Ella and Mrs. Suchitra Ella founded Bharat Biotech, the first company to establish operations in a biotechnology park in Genome Valley, Hyderabad, India.
1999	The company expanded its capacity to develop around 100 million doses of Revac-B+ annually, becoming the largest manufacturer of Hepatitis B vaccines globally.
2002	The company becomes the first Indian company to receive two grants from the Bill & Melinda Gates Foundation through the Program for Appropriate Technology in Health (PATH) to develop new vaccines against Malaria and Rotavirus.
2005	The company made a marketing and manufacturing agreement with Acambis, plc, to develop a Japanese Encephalitis vaccine.
2012	Bharat Biotech and the University of Maryland collaborated to receive a $4 million strategic translation award from the Wellcome Trust for the clinical development of a new life-saving conjugate vaccine for Invasive Non-Typhoidal Salmonella (iNTS).
2016	Bharat Biotech has become one of the first companies to file a global patent for the Zika vaccine.
2020	The company's COVAXIN, an Indigenous COVID-19 vaccine, completed preclinical testing and phases 1 and 2 clinical trials. It is commencing the largest-ever phase 3 clinical trials to evaluate safety and efficacy nationwide.
2021	Bharat Biotech's COVID-19 vaccine, Covaxin, has received approval for emergency use in Children 12 - 18.
2022	Bharat Biotech International Ltd. (BBIL) announced that iNCOVACC (BBV154) has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Restricted Use in Emergency Situations for adults 18 and older.